These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9252393)

  • 1. Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN.
    van 't Veer C; Kalafatis M; Bertina RM; Simioni P; Mann KG
    J Biol Chem; 1997 Aug; 272(33):20721-9. PubMed ID: 9252393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor.
    van 't Veer C; Golden NJ; Kalafatis M; Mann KG
    J Biol Chem; 1997 Mar; 272(12):7983-94. PubMed ID: 9065469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.
    van 't Veer C; Mann KG
    J Biol Chem; 1997 Feb; 272(7):4367-77. PubMed ID: 9020158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Normal" thrombin generation.
    Butenas S; van't Veer C; Mann KG
    Blood; 1999 Oct; 94(7):2169-78. PubMed ID: 10498586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
    van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
    Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
    Bajzar L; Kalafatis M; Simioni P; Tracy PB
    J Biol Chem; 1996 Sep; 271(38):22949-52. PubMed ID: 8798478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
    Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
    J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase.
    Mast AE; Broze GJ
    Blood; 1996 Mar; 87(5):1845-50. PubMed ID: 8634431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.
    Nicolaes GA; Tans G; Thomassen MC; Hemker HC; Pabinger I; Varadi K; Schwarz HP; Rosing J
    J Biol Chem; 1995 Sep; 270(36):21158-66. PubMed ID: 7673148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN).
    van 't Veer C; Golden NJ; Kalafatis M; Simioni P; Bertina RM; Mann KG
    Blood; 1997 Oct; 90(8):3067-72. PubMed ID: 9376587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population.
    Dielis AW; Castoldi E; Spronk HM; van Oerle R; Hamulyák K; Ten Cate H; Rosing J
    J Thromb Haemost; 2008 Jan; 6(1):125-31. PubMed ID: 17988231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation.
    Váradi K; Siekmann J; Turecek PL; Schwarz HP; Marder VJ
    Thromb Haemost; 1999 Dec; 82(6):1673-9. PubMed ID: 10613654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
    Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
    Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the tissue factor pathway in initiation of coagulation.
    Mann KG; van't Veer C; Cawthern K; Butenas S
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S3-7. PubMed ID: 9819022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI.
    Miyazawa K; Fogelson AL; Leiderman K
    Biophys J; 2023 Jan; 122(1):99-113. PubMed ID: 36403087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
    Hackeng TM; Seré KM; Tans G; Rosing J
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases.
    Butenas S; van 't Veer C; Mann KG
    J Biol Chem; 1997 Aug; 272(34):21527-33. PubMed ID: 9261172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
    Chowdary P
    Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of inactivation of human factor V and human factor Va by activated protein C.
    Kalafatis M; Rand MD; Mann KG
    J Biol Chem; 1994 Dec; 269(50):31869-80. PubMed ID: 7989361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.